Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET
Company Participants
AJ Bergmann - CFO
Linda Marban - CEO
Conference Call Participants
Joseph Pantginis - H.C. Wainwright
Michael Okunewitch - Maxim Group
Aydin Huseynov - Ladenburg
Brian Corday - BullBear Partners
Operator
Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Mr. AJ Bergmann, Capricor's Chief Financial Officer. Mr. Bergmann, you may begin.
AJ Bergmann
Thank you and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward looking statements during today's call. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future research and development plans, including our anticipated conduct and timing of preclinical and clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, manufacturing capabilities, potential milestone payments and our possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
With that, I'll turn the call over to Linda Marban, Chief Executive Officer.
Linda Marban
Thank you, AJ. Good afternoon and thank you for joining our fourth quarter and full year 2022 conference call today. We are pleased with the progress we have made over the past year and into the first few months of 2023. Today, I will provide important updates on our Duchenne Muscular Dystrophy program, our exosome platform, as well as corporate updates.
These past 15 months for Capricor and our CAP-1002 Duchenne program have seen many highlights and we continue to execute on our three key priorities for our DMD program, which are as follows. First, advancing our HOPE-3 Phase 3 trial. Second, is continuing to engage with the FDA to bring CAP-1002 to patients as expeditiously as possible. And the third is securing commercial partnerships outside of the United States to ensure that CAP-1002 reaches patients with DMD around the world.